A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer ; volume:26 ; number:1 ; day:26 ; month:2 ; year:2024 ; pages:1-10 ; date:12.2024
Breast cancer research ; 26, Heft 1 (26.2.2024), 1-10, 12.2024
- Urheber
-
Shatsky, Rebecca A.
Batra-Sharma, Hemali
Helsten, Teresa
Schwab, Richard B.
Pittman, Emily I.
Pu, Minya
Weihe, Elizabeth
Ghia, Emanuela M.
Rassenti, Laura Z.
Molinolo, Alfredo
Cabrera, Betty
Breitmeyer, James B.
Widhopf, George F.
Messer, Karen
Jamieson, Catriona
Kipps, Thomas J.
Parker, Barbara A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-024-01782-0
- URN
-
urn:nbn:de:101:1-2405152131258.716218978540
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shatsky, Rebecca A.
- Batra-Sharma, Hemali
- Helsten, Teresa
- Schwab, Richard B.
- Pittman, Emily I.
- Pu, Minya
- Weihe, Elizabeth
- Ghia, Emanuela M.
- Rassenti, Laura Z.
- Molinolo, Alfredo
- Cabrera, Betty
- Breitmeyer, James B.
- Widhopf, George F.
- Messer, Karen
- Jamieson, Catriona
- Kipps, Thomas J.
- Parker, Barbara A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer